Clinicopathological Spectrum and Immunohistochemical Expression of CDX2, E-cadherin and Her-2/Neu Markers in Gastric Carcinoma: A Tertiary Centre Experience
Neha Bansal, Chhanda Das, Ankita Pranab Mandal, Mamata Guha Mallick Sinha, Abhimanyu Basu
A
BSTRACT
Introduction:
Gastric carcinoma (GC) is one of the leading causes of cancer-related mortality worldwide. During gastric carcinogenesis, an accumulation of genetic and molecular abnormalities occurs. Understanding these has led to the application of molecular pathology in prevention, early diagnosis, tumor classification and therapeutic intervention. The aim was to study the clinicopathological spectrum of GC and to review the immunohistochemical expression of CDX2, E-cadherin and HER-2/neu.
Materials and Methods:
This hospital-based observational, cross-sectional study was conducted from January 2021 to June 2022 on 50 cases at our department of pathology in a tertiary care hospital. Patients had undergone gastrectomy and the specimens were examined at the Department of Pathology. All the specimens were subjected to thorough histopathologic examination and IHC study of CDX2, E-cadherin and HER-2/neu were done.
Results:
Most common age group affected was 41–60 years with male: female ratio of 2.1:1. The most common location was noted in the pyloric region (48%). Most cases were identified as tubular adenocarcinoma (42%). There was significant correlation noted between CDX2 expression and histological subtypes (
Conclusion:
Delay in diagnosis along with the limitation of therapeutic options are the factors that contribute to the extremely poor prognosis of GC. Hence, the contribution of these genetic markers towards early diagnosis, prediction of progression and prognosis along with newer therapeutic modalities could be of immense benefit in GC patients.